Skip to content

Effect of Hyaluronan-enriched Medium on the Cumulative Ongoing Pregnancy Rate.

Effect of Hyaluronan-enriched Medium on the Cumulative Ongoing Pregnancy Rate: a Prospective Randomized Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04697823
Acronym
TETHER
Enrollment
400
Registered
2021-01-06
Start date
2021-01-01
Completion date
2026-12-31
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyaluronan-EnRiched Medium, Randomized Controlled Trial

Brief summary

Assessing whether the use of hyaluronan-enriched transfer medium can increase the cumulative ongoing pregnancy rate

Interventions

OTHERuse of hyaluronan-enriched transfer medium

In the study group, an embryo transfer will be performed in hyaluronan-enriched transfer medium

Sponsors

KU Leuven
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Masking description

double blind

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients with own oocytes/embryos; * Patients with female age at 1st OR in the study \<40 year; * Patients planned for a 2nd oocyte retrieval, with no clinical ongoing pregnancy after the previous oocyte retrieval * Patients planned for a 3rd oocyte retrieval with no clinical ongoing pregnancy after previous oocyte retrievals * Patients with female age at 1st OR in the study \<40 year; * Patients with BMI ≤32; * Patients with written informed consent;

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
number of transfers needed to reach ongoing pregnancyongoing defined as a pregancy with a viable fetus with FHB at 12 weeks of pregnancyThe primary outcome parameter is the number of transfers needed to reach ongoing pregnancy (ongoing defined as a pregancy with a viable fetus with FHB at 12 weeks of pregnancy), as a time-to-event outcome variable. Patients that do not reach pregnancy, are censored at their last transfer.

Secondary

MeasureTime frameDescription
number of transfers needed to reach clinical pregnancy, life birth, miscarriage, multiple pregnancyuntil Live birth: 9 months after ETclinical pregnancy is defined as a pregnancy with at least one intrauterine (IU) or extrauterine (EU) fetal sac at 6-7 weeks of pregnancy)

Countries

Belgium

Contacts

CONTACTSophie Debrock, PhD
sophie.debrock@uzleuven.be0032016340812

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026